Buprenorphine supply by community pharmacists in Victoria, Australia: Perceptions, experiences and key issues identified

Drug and Alcohol Review

Volumn 26, Issue 2, 2007, Pages 143-151

  Nielsen, Suzanne ^a,b   Dietze, Paul ^a,c   Dunlop, Adrian ^a   Muhleisen, Peter ^a   Lee, Nicole ^a   Taylor, David ^b  

^a TURNING POINT ALCOHOL AND DRUG CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Buprenorphine diversion; Community pharmacy; Supervised dosing

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANTAGONIST;

ARTICLE; AUSTRALIA; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG ADMINISTRATION ROUTE; EPIDEMIOLOGY; HEALTH PERSONNEL ATTITUDE; HEALTH SERVICE; HEROIN DEPENDENCE; HUMAN; ORGANIZATION AND MANAGEMENT; PHARMACIST; PHARMACY; PREVALENCE; PSYCHOLOGICAL ASPECT; RESIDENTIAL CARE; STATISTICS;

ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; BUPRENORPHINE; CATCHMENT AREA (HEALTH); COMMUNITY PHARMACY SERVICES; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; DRUG ADMINISTRATION ROUTES; HEALTH CARE SURVEYS; HEALTH SERVICES MISUSE; HEROIN DEPENDENCE; HUMANS; METHADONE; NARCOTIC ANTAGONISTS; PHARMACISTS; PREVALENCE;

EID: 33847212143     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230601146645     Document Type: Article

References (23)

1. Ezard N, Lintzeris N, Odgers P, et al. An evaluation of community methadone services in Victoria. Australia: Results of a client survey. Drug Alcohol Rev 1999;18:417-23.
2. Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict/Am Acad Psychiatrists Alcohol Addict 2004;13(Suppl 1):S29-41.
3. Victorian Department of Health Services. The Victorian drug statistics handbook: patterns of drug use and related harm in Victoria. Melbourne: Victorian Department of Human Services, 2004.
4. Muhleisen P, Panjari M, Lee N. Buprenorphine dispensing in a cohort of community pharmacies in Victoria. Australian Pharmacist 2003;22:229-34.
5. Muhleisen P, Lintzeris N, Koutroulis G, et al. Evaluation of methadone dispensing in community pharmacies in Victoria, 1998.
6. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;95:197-205.
7. Herald-Sun. Heroin switch drug warning. Herald Sun, Melbourne, Victoria, 1 December 2002.
8. Jenkinson R, Fry C, Miller P. Victorian drug trends 2002: findings from the Illicit Drug Reporting System (IDRS). National Drug and Alcohol Research Centre Technical Report no.145. Sydney: University of NSW, 2002.
9. Jenkinson R, O'Keeffe B. Victorian drug trends 2004: findings from the Illicit Drug Reporting System (IDRS). Sydney: University of NSW, 2004:1-81.
10. Aboltins CA, Allen P, Daffy JR. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Med J Aust 2005;182:427.
11. Cassoux N, Bodaghi B, Lehoang P, Edel Y. Presumed ocular candidiasis in drug misusers after intravenous use of oral high dose buprenorphine (Subutex). Br J Ophthalmol 2002;86:940-1.
12. Loo HW, Yam AKT, Tan TC, Peng YP, Teoh LC. Severe upper limb complications from parenteral abuse of Subutex. Ann Acad Med Sing 2005;34:575-8.
13. Reynaud M, Tracqui A, Petit G, Potard D, Courty P. Six deaths linked to misuse of buprenorphine - benzodiazepine combinations. Am J Psychiatry 1998;155:448-9.
14. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001;121:65-9.
15. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998;22:430-4.
16. Buprenorphine Diversion. Drugs and poisons unit newsletter, Sect. p1. May 2003.
17. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004; issue 3:CD002207.
18. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-16.
19. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001;96:683-90.
20. Supervision of buprenorphine doses. Drugs and poisons unit newsletter, Sect. p4. Melbourne: Department of Human Services, November 2002.
21. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175-81.
22. Jenkinson R, O'Keeffe B. Victorian drug trends 2004: findings from the Illicit Drug Reporting System (IDRS). National Drug and Alcohol Research Centre Technical Report no.212. Sydney: University of NSW, 2004.
23. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100:197-205.